UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 240

Sortiert nach

Adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease

Alimentary pharmacology & therapeutics, 2014-11, Vol.40 (9), p.1044-1055

2014

Link zum Volltext

Verfügbarkeit prüfen

Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo‐controlled study

Alimentary pharmacology & therapeutics, 2013-01, Vol.37 (2), p.252-262

2013

Link zum Volltext

Verfügbarkeit prüfen

Treatment of ulcerative colitis with adalimumab or infliximab: long‐term follow‐up of a single‐centre cohort

Alimentary pharmacology & therapeutics, 2010-08, Vol.32 (4), p.522-528

2010

Link zum Volltext

Verfügbarkeit prüfen

Prevalence of Epstein–Barr Virus in a population of patients with inflammatory bowel disease: a prospective cohort study

Alimentary pharmacology & therapeutics, 2013-11, Vol.38 (10), p.1248-1254

2013

Link zum Volltext

Verfügbarkeit prüfen

Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease

Alimentary pharmacology & therapeutics, 2013-09, Vol.38 (5), p.447-459

2013

Link zum Volltext

Verfügbarkeit prüfen

Maintenance of clinical benefit in Crohn’s disease patients after discontinuation of infliximab: long‐term follow‐up of a single centre cohort

Alimentary pharmacology & therapeutics, 2010-11, Vol.32 (9), p.1129-1134

2010

Link zum Volltext

Verfügbarkeit prüfen

Lactobacillus species prevents colitis in interleukin 10 gene–deficient mice

Gastroenterology (New York, N.Y. 1943), 1999-05, Vol.116 (5), p.1107-1114

1999

Link zum Volltext

Verfügbarkeit prüfen

A one‐hour infusion of infliximab during maintenance therapy is safe and well tolerated: a prospective cohort study

Alimentary pharmacology & therapeutics, 2011-07, Vol.34 (2), p.181-187

2011

Link zum Volltext

Verfügbarkeit prüfen

Steroid-sparing properties of sargramostim in patients with corticosteroid-dependent Crohn’s disease: a randomised, double-blind, placebo-controlled, phase 2 study

Gut, 2009-10, Vol.58 (10), p.1354-1362

2009

Link zum Volltext

Verfügbarkeit prüfen

Clinical, endoscopic and radiographic outcomes with ustekinumab in medically‐refractory Crohn's disease: real world experience from a multicentre cohort

Alimentary pharmacology & therapeutics, 2017-05, Vol.45 (9), p.1232-1243

2017

Link zum Volltext

Verfügbarkeit prüfen

A Comparison of Methotrexate with Placebo for the Maintenance of Remission in Crohn's Disease

The New England journal of medicine, 2000-06, Vol.342 (22), p.1627-1632

2000

Link zum Volltext

Verfügbarkeit prüfen

Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial

Gut, 2007-09, Vol.56 (9), p.1232-1239

2007

Link zum Volltext

Verfügbarkeit prüfen

Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease

Gastroenterology (New York, N.Y. 1943), 1999-09, Vol.117 (3), p.527-535

1999

Link zum Volltext

Verfügbarkeit prüfen

Multiple doses of intravenous Interleukin 10 in steroid-refractory Crohn's disease

Gastroenterology (New York, N.Y. 1943), 1997-08, Vol.113 (2), p.383-389

1997

Link zum Volltext

Verfügbarkeit prüfen

imbalance in mucosal cytokine profile causes transient intestinal inflammation following an animal's first exposure to faecal bacteria and antigens

Clinical and experimental immunology, 2010-07, Vol.161 (1), p.187-196

2010

Link zum Volltext

Verfügbarkeit prüfen

Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's disease

Alimentary pharmacology & therapeutics, 2015-11, Vol.42 (10), p.1170-1181

2015

Link zum Volltext

Verfügbarkeit prüfen

Systematic review with meta‐analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis

Alimentary pharmacology & therapeutics, 2018-06, Vol.47 (12), p.1578-1596

2018

Link zum Volltext

Verfügbarkeit prüfen

Infliximab Maintenance Therapy for Fistulizing Crohn's Disease

The New England journal of medicine, 2004-02, Vol.350 (9), p.876-885

2004

Link zum Volltext

Verfügbarkeit prüfen

Interleukin 10 prevents cytokine-induced disruption of T84 monolayer barrier integrity and limits chloride secretion

Gastroenterology (New York, N.Y. 1943), 1997-07, Vol.113 (1), p.151-159

1997

Link zum Volltext

Verfügbarkeit prüfen

A Randomized, Placebo-Controlled Trial of Certolizumab Pegol (CDP870) for Treatment of Crohn’s Disease

Gastroenterology (New York, N.Y. 1943), 2005-09, Vol.129 (3), p.807-818

2005

Link zum Volltext

Verfügbarkeit prüfen

Review article: acid suppression in non‐variceal acute upper gastrointestinal bleeding

Alimentary pharmacology & therapeutics, 1999-12, Vol.13 (12), p.1565-1584

1999

Link zum Volltext

Verfügbarkeit prüfen

Low-Dose Cyclosporine for the Treatment of Crohn's Disease

The New England journal of medicine, 1994-06, Vol.330 (26), p.1846-1851

1994

Link zum Volltext

Verfügbarkeit prüfen

Endogenous Interleukin-10 Regulates Hemodynamic Parameters, Leukocyte-Endothelial Cell Interactions, and Microvascular Permeability During Endotoxemia

Circulation research, 1998-11, Vol.83 (11), p.1124-1131

1998

Link zum Volltext

Verfügbarkeit prüfen

Quality of Life in Inflammatory Bowel Disease

Journal of clinical gastroenterology, 1992-01, Vol.14 (1), p.15-19

1992

Link zum Volltext

Verfügbarkeit prüfen

Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial

Gut, 2011-06, Vol.60 (6), p.780-787

2011

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 240

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(220)
Mit Volltextzugriff
(187)

Publikationsform

Sprache

Englisch
(240)
Japanisch
(31)

Erscheinungsjahr

n.n

Thema

Science & Technology
(138)
Life Sciences & Biomedicine
(135)
Gastroenterology & Hepatology
(100)
Humans
(99)
Male
(85)
Biological And Medical Sciences
(79)
Medical Sciences
(73)
Female
(57)
Animals
(53)
Adult
(50)
Middle Aged
(39)
Inflammatory Bowel Disease
(38)
Pharmacology. Drug Treatments
(38)
Rats
(33)
Gastroenterology
(31)
Treatment Outcome
(31)
Crohn Disease - Drug Therapy
(28)
Gastroenterology. Liver. Pancreas. Abdomen
(27)
Digestive System
(26)
Crohn's Disease
(25)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease

Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo‐controlled study

Treatment of ulcerative colitis with adalimumab or infliximab: long‐term follow‐up of a single‐centre cohort

Prevalence of Epstein–Barr Virus in a population of patients with inflammatory bowel disease: a prospective cohort study

Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease

Maintenance of clinical benefit in Crohn’s disease patients after discontinuation of infliximab: long‐term follow‐up of a single centre cohort

Lactobacillus species prevents colitis in interleukin 10 gene–deficient mice

A one‐hour infusion of infliximab during maintenance therapy is safe and well tolerated: a prospective cohort study

Steroid-sparing properties of sargramostim in patients with corticosteroid-dependent Crohn’s disease: a randomised, double-blind, placebo-controlled, phase 2 study

Clinical, endoscopic and radiographic outcomes with ustekinumab in medically‐refractory Crohn's disease: real world experience from a multicentre cohort

A Comparison of Methotrexate with Placebo for the Maintenance of Remission in Crohn's Disease

Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial

Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease

Multiple doses of intravenous Interleukin 10 in steroid-refractory Crohn's disease

imbalance in mucosal cytokine profile causes transient intestinal inflammation following an animal's first exposure to faecal bacteria and antigens

Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's disease

Systematic review with meta‐analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis

Infliximab Maintenance Therapy for Fistulizing Crohn's Disease

Interleukin 10 prevents cytokine-induced disruption of T84 monolayer barrier integrity and limits chloride secretion

A Randomized, Placebo-Controlled Trial of Certolizumab Pegol (CDP870) for Treatment of Crohn’s Disease

Review article: acid suppression in non‐variceal acute upper gastrointestinal bleeding

Low-Dose Cyclosporine for the Treatment of Crohn's Disease

Endogenous Interleukin-10 Regulates Hemodynamic Parameters, Leukocyte-Endothelial Cell Interactions, and Microvascular Permeability During Endotoxemia

Quality of Life in Inflammatory Bowel Disease

Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial

Suchergebnisse filtern